Skip to content

PRP Therapy to m. Gluteus Medius During THA

Single Injection of Platelet-rich Plasma (PRP) to m. Gluteus Medius During Total Hip Arthroplasty Using Direct Lateral (Hardinge) Approach

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02607462
Enrollment
80
Registered
2015-11-18
Start date
2015-11-30
Completion date
Unknown
Last updated
2016-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Osteoarthritis

Brief summary

Study purpose is to evaluate perioperative usefulness of Platelet-rich Plasma (PRP) in total hip arthroplasty (THA) surgery. The study is designed as a randomized double blinded study using saline as placebo. The measurement outcomes includes objective variables (MRI, dynamometer) as well as subjective measurements (Oxford Hip Score, Harris Hip Score). Patients are assigned to two different groups, according to a randomization list. PRP (approximately 9ml from which 1ml is delivered to in-house laboratory for the measurement of platelet count) is obtained from venous blood and applied to m. gluteus medius during the closure of modified lateral approach (Hardinge). Study participants are evaluated preoperatively by trained physiotherapist. After surgery, participants undergo clinical evaluation and imaged (MRI) at 3 and 12 months post-operative. In the same time points, strength, Harris Hip Score and Oxford Hip Score. At the end of the study, the nature of the injected substance is revealed to the patients.

Interventions

BIOLOGICALPRP
OTHERPlacebo

Sponsors

Satakunta Central Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinically and radiology confirmed arthritis which treatment is total hip arthroplasty.

Exclusion criteria

* Revision surgery, insulin dependent diabetes and other endocrinology disease, smoking, use of per os cortisone, malignancy, rheumatoid arthritis, any autoimmune disease, alcoholist, previous fracture to hip, patients with diagnosed mental illness, absolute contraindications for MRI study

Design outcomes

Primary

MeasureTime frameDescription
The decrease of T2 weighted signaling between PRP and placebo groupChange from 3 months at 12 monthsQuantitative method of tissue healing

Secondary

MeasureTime frameDescription
Differences in Harris Hip Score points between PRP and placebo groupChange from 3 months at 12 monthsQuality method of post-operative healing
Comparison of hip abduction strengths between PRP and placebo group using dynamometerChange from 3 months at 12 monthsQuantitive method of abduction strengths

Countries

Finland

Contacts

Primary ContactJussi Kosola, MD, PhD
jussi.kosola@helsinki.fi+358442607366
Backup ContactJuha Kukkonen, MD, PhD
juha.kukkonen@utu.fi+358505330095

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026